Response to Simon et al., by Wei, Wei et al.
LETTER TO THE EDITOR Open Access
Response to Simon et al.,
Wei Wei1, Michael J. Keogh1, James W. Ironside2 and Patrick F. Chinnery1*
Please see the related Research article (10.1186/
s40478-016-0404-6) and the related Letter to
the Editor (10.1186/s40478-017-0433-9)
As Simon et al., note, our study [1] was not designed to
study low levels of heteroplasmic mitochondrial DNA
(mtDNA) variants within specific cell types (such as in
the Substantia nigra). In addition, Parkinson’s disease
comprised only 3.2% of our cohort of 1363 post mortem
brains [1]. We agree, therefore, that our findings do not
directly contradict their published observations [2–4].
However, we did show that heteroplasmic mtDNA
mutations are a common finding in the human brain [1].
Both the mean number of heteroplasmic single nucleotide
variants (SNVs, with a variant allele frequency, VAF >10%),
and the mean percentage level of mtDNA heteroplasmy in
several neurodegenerative diseases (Alzheimer’s disease,
frontotemporal dementia-amyotrophic lateral sclerosis,
Creutzfeldt-Jakob disease, and Dementia with Lewy
bodies–Parkinson’s disease [DLB-PD]) were no different to
age-matched controls (Fig. 3 in Wei et al. [1],). In addition,
both the mean number of heteroplasmic variants and the
mean level of mtDNA heteroplasmy were not associated
with age at death in the neurodegenerative disease cases,
nor in controls. Consistent with other studies, many (if not
all) of these variants are likely to have been inherited rather
than acquired as somatic mutations during life [5], and are
therefore highly likely to be present within the Substantia
nigra, despite not being directly sampled. If the mtDNA
variants we detected were contributing to the pathogenesis
of neurodegeneration, we would have expected to see a
difference between diseases cases and controls. If mtDNA
mutations are contributing to cell loss, then one might even
expect to see a reduction in the mutation burden in
affected tissue - but this was not the case in our study (in-
cluding DLB-PD, Fig. 3 & Supplementary Fig. 12 in Wei et
al. [1],), and it was not the case in several studies of Simon
et al. [2–4].
As Simon et al., point out, they have shown that
neurons containing mtDNA mutations are present in
early and pre-clinical Lewy body disorders [2], thus
demonstrating that the presence of a mtDNA mutation
need not necessarily cause immediate neuronal loss. Any
one individual mutation could have been inherited [5]
(and been present from birth at low levels), particu-
larly if it is shared by several cells. Given the inherent
difficulties in studying post mortem tissue, the only
way of definitively solving this issue will be through direct
experimentation in a relevant animal or cell model of
disease. For Parkinson’s disease, we need to know whether
the introduction of mtDNA mutations actually causes
neurodegeneration in the Substantia nigra, and is not just
an innocent bystander in a toxic cellular environment at a
particular phase of the disorder.
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